ArticleEuropean journal of clinical pharmacology2015
Trends in inpatient antiparkinson drug use in the USA, 2001-2012.
Article in European journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Case Definitions and Data Sources for NNCSS Parkinson Disease Surveillance: A Systematic Review.JAMA network open · 2026Pooled it
- Trends in Antipsychotic Drug Use in the United States, 2000-2016.Pharmacy (Basel, Switzerland) · 2026Article
- Assessing healthcare resource utilization burden and unmet treatment needs in patients with Parkinson's disease: results from a real-world study.Journal of comparative effectiveness research · 2025Article
- Behavioural analysis of factors influencing prescribing for neurodegenerative diseases: A rapid review.PloS one · 2025Review
- Drug utilization study of antiparkinsonian medication in Romania during 25 years.Frontiers in pharmacology · 2025Article
- Anticholinergic drugs for parkinsonism and other movement disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Antiparkinsonian Medication Reconciliation as a Strategy to Improve Safety by Preventing Medication Errors.Movement disorders clinical practice · 2023Article
- Course of Impulse Control Disorder Symptoms in Parkinson's Disease: Deep Brain Stimulation Versus Medications.Movement disorders clinical practice · 2023Article
- Prescribing patterns and determinants for elderly patients with Parkinson's disease in Japan: a retrospective observational study using insurance claims databases.Frontiers in neurology · 2023Article
- Time until modification of antiparkinsonian therapy in a group of patients from Colombia.Revista de neurologia · 2023Article
- Dopamine agonist monotherapy utilization in patients with Parkinson's disease.Clinical parkinsonism & related disorders · 2023Article
- Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease.NPJ Parkinson's disease · 2022Article
- Potential utility of amantadine DR/ER in persons with Parkinson's disease meeting 5-2-1 criteria for device aided therapy.Clinical parkinsonism & related disorders · 2022Review
- Anticholinergic Medication Burden in Parkinson's Disease Outpatients.Journal of Parkinson's disease · 2022Article
- Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe?Movement disorders clinical practice · 2021Review
- Review of medicine utilization for Parkinson's disease management: the Bulgarian perspective.Journal of public health research · 2021Article
- Factors affecting the choice of first-line therapy in Parkinson's disease patients in Wales: A population-based study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021Article
- Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors.Parkinson's disease · 2021Article
- Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database.eNeurologicalSci · 2020Article
- Utilization Patterns of Amantadine in Parkinson's Disease Patients Enrolled in the French COPARK Study.Drugs & aging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
Abstract
purposeAlthough therapeutic options and clinical guidelines for Parkinson's disease (PD) have changed significantly in the past 15 years, prescribing trends in the USA remain unknown. The purpose of this population-based cohort study was to examine patterns of inpatient antiparkinson drug use between January 2001 and December 2012 in relation to clinical guideline publication, drug introduction/withdrawal, and emerging safety concerns.
methodsA total of 16,785 inpatients receiving pharmacological treatment for PD were identified in the Cerner Health Facts database. Our primary outcome was standardized (age, sex, race, and census region) annual prevalence of antiparkinson drug use. We also examined antiparkinson medication trends and polypharmacy by age and sex.
resultsThe most frequently prescribed antiparkinson drugs between 2001 and 2012 were levodopa (85%) and dopamine agonists (28%). Dopamine agonist use began declining in 2007, from 34 to 27% in 2012. The decline followed publication of the American Academy of Neurology's practice parameter refuting levodopa toxicity, pergolide withdrawal, and pramipexole label revisions. Despite safety concerns for cognitive impairment and falls, individuals ≥80 years of age demonstrated stable rates of dopamine agonist use from 2001 to 2012. Polypharmacy was most common in younger patients.
conclusionsDopamine agonist use declined from 2007 to 2012, suggesting that increased awareness of safety issues and practice guidelines influenced prescribing. These events appear to have minimally influenced treatment provided to older PD patients. Antiparkinson prescribing trends indicate that safety and best practice information may be communicated effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.